Lilly Licenses OSI Glucokinase Activator Program For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The nearly $400 million deal gives Lilly exclusive rights to OSI’s GKA drugs, including a lead compound in Phase I studies.
You may also be interested in...
Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion
TOKYO - Astellas is weighing its options for metabolic subsidiary Prosidion, likely divesting all or part of it, as the company continues its integration, and shedding, of OSI Pharmaceuticals. If it sells off Prosidion, Astellas will be left with few pipeline entries in the diabetes space
Array BioPharma Set To Raise Funds By Partnering Discovery Programs
Early partnering of preclinical glucokinase activator program would allow Array to stay focused on oncology and inflammation.
Array BioPharma Set To Raise Funds By Partnering Discovery Programs
Early partnering of preclinical glucokinase activator program would allow Array to stay focused on oncology and inflammation.